American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy

Gastroenterology. 2015 Jan;148(1):215-9; quiz e16-7. doi: 10.1053/j.gastro.2014.10.039. Epub 2014 Oct 31.
No abstract available

Publication types

  • Practice Guideline
  • Review

MeSH terms

  • Antiviral Agents / therapeutic use*
  • Biomarkers / blood
  • DNA, Viral / blood
  • Hepatitis B / diagnosis
  • Hepatitis B / drug therapy*
  • Hepatitis B / immunology
  • Hepatitis B / prevention & control*
  • Hepatitis B / virology
  • Hepatitis B Antibodies / blood
  • Hepatitis B Surface Antigens / blood
  • Hepatitis B virus / drug effects*
  • Hepatitis B virus / genetics
  • Hepatitis B virus / immunology
  • Hepatitis B virus / pathogenicity
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Recurrence
  • Treatment Outcome
  • Viral Load
  • Virus Activation / drug effects*

Substances

  • Antiviral Agents
  • Biomarkers
  • DNA, Viral
  • Hepatitis B Antibodies
  • Hepatitis B Surface Antigens
  • Immunosuppressive Agents